Skip to main content
. 2021 Aug 26;22(5):1222. doi: 10.3892/etm.2021.10656

Figure 2.

Figure 2

RvD2 inhibits NLRP3 inflammasome activation in macrophages. (A-C) IL-1β level in the supernatant of macrophages following treatment with (A) poly(dA/dT), (B) MDP and (C) flagellin (n=3). (D) IL-1β level in the supernatant of macrophages treated with RvD2 (10 nM) 30 min before LPS stimulation, 30 min before Nig treatment or 15 min after Nig treatment (n=3). (E and F) Western blot analysis and quantification of pro-caspase 1, Cas-1-p20 in supernatant and of pro-IL-1β, NLRP3, pro-caspase 1, Cas-1-p20 and β-actin in cell lysate after indicated treatments (n=3). *P<0.05. Cas, caspase; LPS, lipopolysaccharide; MDP, muramyl dipeptide; Nig, nigericin; NLRP3, NLR family pyrin domain containing 3; RvD2, resolvin D2.